Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats
Simone Anna Melander, Alexandra Louise Møller, Khaled Elhady Mohamed, Daniel Guldager Kring Rasmussen, Federica Genovese, M.A. Karsdal, Kim Henriksen, Anna Thorsø Larsen
Abstract
These studies describe the beneficial effects of using a dual amylin and calcitonin receptor agonist (DACRA) for diabetes-related kidney complications. DACRA treatment reduced levels of serological biomarkers associated with kidney fibrosis. These reductions were further reflected by reduced collagen expression in diabetic kidneys. In general, these results validate the use of serological biomarkers while demonstrating the potential effect of DACRAs in treating diabetes-related long-term complications.
Topics & Concepts
AmylinEndocrinologyInternal medicineKidneyFibrosisDiabetes mellitusMedicineType 2 diabetesKidney diseaseCalcitoninCalcitonin receptorReceptorCalcitonin gene-related peptideNeuropeptideIsletAdvanced Glycation End Products researchChronic Kidney Disease and DiabetesDiabetes Treatment and Management